(Q58415977)

English

Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: A phase 1/2 study of the acute leukemia French association

article

In more languages

Statements

scholarly article

0 references

Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: A phase 1/2 study of the acute leukemia French association (English)

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Sylvain Chantepie

object named as

Sylvain Chantepie

7

0 references

object named as

Sylvie Chevret

10

0 references

11

object named as

Hervé Dombret

0 references

author name string

Hassan Farhat

1

0 references

Oumedaly Reman

2

0 references

Emmanuel Raffoux

3

0 references

Celine Berthon

4

0 references

Cécile Pautas

5

0 references

Leila Kammoun

6

0 references

Claude Gardin

8

0 references

Philippe Rousselot

9

0 references

Sylvie Castaigne

12

0 references

publication date

10 November 2011

0 references

American Journal of Hematology

0 references

87

0 references

1

0 references

62-65

0 references

Drug therapy for acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22201

21 January 2018

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22201

21 January 2018

Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22201

21 January 2018

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22201

21 January 2018

High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22201

21 January 2018

Targeting of the CD33-calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22201

21 January 2018

Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22201

21 January 2018

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22201

21 January 2018

Randomized study of intensified anthracycline doses for induction and recombinant interleukin-2 for maintenance in patients with acute myeloid leukemia age 50 to 70 years: results of the ALFA-9801 study

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22201

21 January 2018

Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22201

21 January 2018

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22201

21 January 2018

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FAJH.22201

21 January 2018

Identifiers

10.1002/AJH.22201

0 references

PubMed publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q58415977&oldid=1584562720"